Odyssey Therapeutics, Inc.

All statements other than statements of historical facts are forward-looking statements, including, but not limited to, statements regarding our business strategy; the future clinical development, efficacy, safety, and therapeutic potential of our product candidates; expectations regarding the initiation, design, and reporting of data from our preclinical studies and clinical trials; future financial results; anticipated manufacturing plans; expectations regarding regulatory approval of any of our product candidates; and plans for future operations or other characterizations of future events.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026

In some cases, you can identify forward-looking statements through the use of words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negatives of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026

Inflammatory responses to RNA or DNA are a root cause of many autoimmune diseases and a driver of pathogenic B cell expansion and autoantibody production Type I IFN Pathogenic B cells Cytokines / Chemokines TASL We Believe SLC15A4 Is an Ideal Target in a Validated Pathway to Treat Diseases Driven by B Cells or Pathogenic RNA and DNA Sources: Immunity 2006;25:429; Nat Immunol 2022;23:1457; PLoS One 2021;16:e0244439; Proc Natl Acad Sci U S A 2013;110:2940; Proc Natl Acad Sci U S A 2022;119:e2200544119; Nat Commun 2025;16:968; Proc Natl Acad Sci U S A 2010;107:10154; PLoS One 2014;9:e103478; J Immunol 2010;184:796.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026

Enpatoran Ph3 initiated March/April 2026 Afimetoran Ph2 completed June 2026 E6742 Ph2 initiated March 2026 MHV370 Discontinued for strategic reasons N/A Phase 1 Ex Vivo Stimulation Assays Correlate With Activity in Lupus Patients Notes: CLASI = cutaneous lupus erythematosus disease area and severity index; (1) phase 1 evaluated 200 mg QD and phase 2 used 100 mg BID.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026

Forward-looking statements reflect Odyssey’s current expectations and involve risks and uncertainties that could cause actual results to differ materially.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026

These include the inherent limitations of an open-label trial without a concurrent placebo control; potential uncertainty about exploratory transcriptomic findings; the possibility of different outcomes in future trials; clinical, regulatory, competitive and third-party risks; and other factors described under “Risk Factors” in Odyssey’s most recent Form 10-Q and other SEC filings.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026

These statements are not guarantees of future performance and involve risks and uncertainties, some of which are beyond our control, and you are cautioned not to place undue reliance on any forward-looking statements.

SEC original ↗Odyssey Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 20, 2026